Literature DB >> 18972346

MRI assessment of basal ganglia iron deposition in Parkinson's disease.

Lauren I Wallis1, Martyn N J Paley, Jacqueline M Graham, Richard A Grünewald, Emma L Wignall, Harriet M Joy, Paul D Griffiths.   

Abstract

PURPOSE: To estimate the levels of basal ganglia iron levels in Parkinson's disease (PD) using the PRIME MR sequence at 3.0 Tesla, in relation to patients' motor symptom severity.
MATERIALS AND METHODS: Seventy patients with PD and 10 healthy controls underwent assessment of movement and MR imaging. Mean R2' relaxation rates were recorded in the substantia nigra, frontal white matter and in the rostral, mid, and caudal putamen.
RESULTS: R2' relaxation rates were significantly higher in patients with PD than in healthy controls. R2' in the most affected substantia nigra correlated with PD patients' motor symptom severity, but not with disease duration. Neuroradiological observation revealed a rostral to caudal "gradient" of putaminal hypointensity. This was substantiated by the finding that the mid and caudal putamen showed significantly higher R2' relaxation rates, consistent with higher iron levels in PD relative to the healthy controls.
CONCLUSION: MRI at 3.0 Tesla suggests that substantia nigra iron levels are increased and linked to the severity of motor symptoms experienced in PD. Findings consistent with increased iron levels in the PD putamen are shown, in a region-specific rostral to caudal gradient. Copyright (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972346     DOI: 10.1002/jmri.21563

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  66 in total

1.  Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease.

Authors:  Y Murakami; S Kakeda; K Watanabe; I Ueda; A Ogasawara; J Moriya; S Ide; K Futatsuya; T Sato; K Okada; T Uozumi; S Tsuji; T Liu; Y Wang; Y Korogi
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-12       Impact factor: 3.825

Review 2.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

Review 3.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

4.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

5.  Valproic acid attenuates nitric oxide and interleukin-1β production in lipopolysaccharide-stimulated iron-rich microglia.

Authors:  Nootchanat Mairuae; Poonlarp Cheepsunthorn
Journal:  Biomed Rep       Date:  2018-02-09

6.  Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease.

Authors:  Naying He; Pei Huang; Huawei Ling; Jason Langley; Chunlei Liu; Bei Ding; Juan Huang; Hongmin Xu; Yong Zhang; Zhongping Zhang; Xiaoping Hu; Shengdi Chen; Fuhua Yan
Journal:  NMR Biomed       Date:  2016-05-18       Impact factor: 4.044

7.  T1rho and T2rho MRI in the evaluation of Parkinson's disease.

Authors:  I Nestrasil; S Michaeli; T Liimatainen; C E Rydeen; C M Kotz; J P Nixon; T Hanson; Paul J Tuite
Journal:  J Neurol       Date:  2010-01-08       Impact factor: 4.849

8.  3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.

Authors:  Kimihiro Ogisu; Kohsuke Kudo; Makoto Sasaki; Ken Sakushima; Ichiro Yabe; Hidenao Sasaki; Satoshi Terae; Mitsuhiro Nakanishi; Hiroki Shirato
Journal:  Neuroradiology       Date:  2013-03-23       Impact factor: 2.804

9.  Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Robert Stephens; Kai C Sonntag
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

10.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.